Comparing steroid tapering with inebilizumab in NMOSD
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests whether a slower or faster reduction of steroid pills, combined with the drug inebilizumab, is more effective for people with NMOSD (a rare autoimmune disease affecting the nerves). The study aims to find the best way to manage treatment after an attack.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of NMOSD (neuromyelitis optica spectrum disorder).
- You must test positive for a specific antibody called AQP4-IgG in your blood.
- You must have had a recent NMOSD attack within the last month, and be currently taking 60 mg of prednisone (a steroid) daily.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.
- You must not have serious infections, active hepatitis B or C, HIV, or certain liver or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
This trial tests a new medicine called inectolizumab, combined with optimized steroid therapy, for people having their first attack of neuromyelitis optica spectrum disorder (NMOSD). The goal is to see if this combination better controls the disease and prevents future attacks.
This trial studies inebilizumab to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are having an acute attack. It aims to reduce ongoing nerve damage and disability after a recent flare, alongside standard steroid treatment.
This trial studies whether inebilizumab can reduce illness activity in children with neuromyelitis optica spectrum disorder (NMOSD), a condition that can cause attacks affecting the eyes and spinal cord. It focuses on kids who have had recent relapses, meaning symptoms came back or worsened.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
Hear when a new Neuromyelitis Optica Spectrum Disorders (NMOSD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.